Page 11 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gene therapy legend R. Jude Samulski, Ph.D., co-founder and chief scientific officer of Asklepios BioPharmaceutical (AskBio) since the company was established in 2001, is leaving the CSO job but remaining on the company board.AskBio announced that Mansuo Shannon, Ph.D., becomes CSO effective today. Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she also served as CSO.

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran continue to show polyspecific T cell responses up to three...

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran continue to show polyspecific T cell responses up to three...

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122,...

Investegate announcements from Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer